The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human study of, NUC-7738, a 3'dA phosphoramidate, in patients with advanced solid tumors or lymphoma (NuTide 701).
 
Hagen P Schwenzer
Research Funding - Nucana
 
Stefan N. Symeonides
Consulting or Advisory Role - Agalimmune (Inst); Bicycle Therapeutics (Inst); Ellipses Pharma (Inst); EUSA Pharma (Inst); Novartis (Inst); OCTIMET (Inst); Vaccitech (Inst)
Research Funding - Boston Pharmaceuticals (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Sierra Oncology (Inst); Tioma Therapeutics (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ipsen; Ipsen
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); Bristol-Myers Squibb; Pfizer (I); Roche/Genentech
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; MSD Oncology; Novartis; Octimet; Pierre Fabre; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Gareth P Bond
Research Funding - Nucana
Travel, Accommodations, Expenses - Abbvie
 
Sarah Patricia Blagden
Stock and Other Ownership Interests - RNA Guardian; RNA Guardian (I)
Speakers' Bureau - Clovis Oncology; OCTIMET
Research Funding - Incyte (Inst); Nucana (Inst); octimet (Inst); Piqur (Inst); Redx Pharma (Inst); Sierra Pharma (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - WO 2016075455 A1 circulating LARP1
Travel, Accommodations, Expenses - Nucana; Tesaro